Versant boosts Canadian presence with key appointments

Mark Henderson
February 14, 2017

Versant Ventures has made key appointments in Canada, the US and Switzerland in advance of the launch of its sixth fund, which is expected to reach $400 million. The San Francisco-based venture fund has $2.3 billion under management and has been increasingly active in Canada, most recently teaming with Bayer AG to invest $300 million in the Toronto-based life sciences start-up, Blue Rock Therapeutics. The Canadian venture partners are Dr Mary Haak-Frendscho (Toronto), CEO of Blueline Bioscience located at the MaRS Disovery District, and Lloyd Segal (Montreal) who will lead a new Canada-based series ‘A’ oncology start-up backed by Versant.


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.